Vericel Corporation News Releases http://investors.vcel.com/ Vericel Corporation News Releases en Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019 http://investors.vcel.com/news-releases/news-release-details/vericel-present-2019-ubs-global-healthcare-conference-wednesday CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 2019 UBS Global Wed, 15 May 2019 08:00:00 -0400 Vericel Corporation News Releases 18096 Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance http://investors.vcel.com/news-releases/news-release-details/vericel-reports-first-quarter-2019-financial-results-and-raises MACI Revenue Increased 38% Over First Quarter 2018 Positive Cash Flow in First Quarter Announced Exclusive License Agreement with MediWound for North American Rights to NexoBrid Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation Tue, 07 May 2019 07:00:09 -0400 Vericel Corporation News Releases 18056 Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns http://investors.vcel.com/news-releases/news-release-details/vericel-enters-exclusive-license-agreement-mediwound-north Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care Market CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a Tue, 07 May 2019 01:59:51 -0400 Vericel Corporation News Releases 18041 Vericel to Report First-Quarter 2019 Financial Results on May 7, 2019 http://investors.vcel.com/news-releases/news-release-details/vericel-report-first-quarter-2019-financial-results-may-7-2019 CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2019 financial results and Thu, 25 Apr 2019 08:30:00 -0400 Vericel Corporation News Releases 17961 Vericel to Present at Needham Healthcare Conference http://investors.vcel.com/news-releases/news-release-details/vericel-present-needham-healthcare-conference-0 CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Needham Wed, 03 Apr 2019 08:30:09 -0400 Vericel Corporation News Releases 17856 Vericel to Present at Multiple Upcoming Investor Conferences http://investors.vcel.com/news-releases/news-release-details/vericel-present-multiple-upcoming-investor-conferences-0 CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences. Nick Colangelo, president and CEO will present Mon, 04 Mar 2019 08:30:41 -0500 Vericel Corporation News Releases 17781 Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance http://investors.vcel.com/news-releases/news-release-details/vericel-reports-fourth-quarter-and-full-year-2018-financial Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017 Full-Year 2018 Product Revenues of $90.9 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in Tue, 26 Feb 2019 07:30:13 -0500 Vericel Corporation News Releases 17751 Vericel to Participate in Multiple Upcoming Investor Conferences http://investors.vcel.com/news-releases/news-release-details/vericel-participate-multiple-upcoming-investor-conferences CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced participation in multiple upcoming investor conferences. Nick Colangelo, president and CEO and Gerard Wed, 20 Feb 2019 08:30:17 -0500 Vericel Corporation News Releases 17741 Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019 http://investors.vcel.com/news-releases/news-release-details/vericel-report-fourth-quarter-2018-financial-results-february-26 CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2018 financial results and Tue, 12 Feb 2019 08:30:21 -0500 Vericel Corporation News Releases 17691 Vericel to Present at the 21st Annual Needham Growth Conference http://investors.vcel.com/news-releases/news-release-details/vericel-present-21st-annual-needham-growth-conference CAMBRIDGE, Mass., Jan. 11, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 21 st Annual Fri, 11 Jan 2019 12:11:47 -0500 Vericel Corporation News Releases 17641